Insulin glargine and lixisenatide Subcutaneous and Potassium Chloride
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Potassium Chloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using lixisenatide together with insulin glargine can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a glucagon-like peptide-1 (GLP-1) receptor agonist with insulin may potentiate the risk of hypoglycemia. GLP-1 receptor agonists lower blood glucose by stimulating insulin secretion and lowering glucagon secretion.
MANAGEMENT: When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.
- "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.
- "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: potassium chloride
Brand name: Kal Potassium 99, Klor-Con, K-Tab, K-Dur, K-Tabs, Micro-K, Kaon, Rum-K
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Potassium Chloride and Dextrose
- Insulin glargine and lixisenatide Subcutaneous-Potassium chloride and sodium chloride
- Insulin glargine and lixisenatide Subcutaneous-Potassium Chloride Capsules
- Insulin glargine and lixisenatide Subcutaneous-Potassium Chloride Extended-Release Capsules
- Insulin glargine and lixisenatide Subcutaneous-Potassium Chloride Extended-Release Tablets
- Insulin glargine and lixisenatide Subcutaneous-Potassium Chloride in Lactated Ringers and Dextrose
- Potassium Chloride-Insulin glargine, recombinant Subcutaneous
- Potassium Chloride-Insulin glulisine
- Potassium Chloride-Insulin Glulisine (Cartridges and Pens)
- Potassium Chloride-Insulin Glulisine (Vials)
- Potassium Chloride-Insulin glulisine Subcutaneous
- Potassium Chloride-Insulin human inhaled Inhalation